T. Rowe Price Associates
MDXG icon

T. Rowe Price Associates’s MiMedx Group MDXG Stock Holding History

T. Rowe Price Associates’s Portfolio MDXG Stock Details MDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$370K Sell
95,989
-18,535
-16% -$67.6K ﹤0.01% 2764
2026
Q1 		$453K Buy
114,524
+24,985
+28% +$126K ﹤0.01% 2508
2025
Q4 		$607K Buy
89,539
+4,700
+6% +$32.9K ﹤0.01% 2306
2025
Q3 		$594K Buy
84,839
+5,536
+7% +$38.5K ﹤0.01% 2298
2025
Q2 		$486K Buy
79,303
+28,119
+55% +$187K ﹤0.01% 2315
2025
Q1 		$389K Buy
51,184
+4,738
+10% +$39.6K ﹤0.01% 2355
2024
Q4 		$447K Buy
46,446
+7,189
+18% +$56K ﹤0.01% 2332
2024
Q3 		$233K Buy
39,257
+1,510
+4% +$10K ﹤0.01% 2593
2024
Q2 		$262K Buy
37,747
+4,769
+14% +$33.5K ﹤0.01% 2486
2024
Q1 		$254K Buy
32,978
+3,806
+13% +$30.6K ﹤0.01% 2510
2023
Q4 		$256K Sell
29,172
-23,857
-45% -$175K ﹤0.01% 2442
2023
Q3 		$387K Sell
53,029
-1,424
-3% -$10.6K ﹤0.01% 2232
2023
Q2 		$360K Buy
54,453
+1,457
+3% +$7.43K ﹤0.01% 2282
2023
Q1 		$181K Buy
52,996
+8,233
+18% +$31.9K ﹤0.01% 2555
2022
Q4 		$124K Buy
44,763
+12,722
+40% +$38K ﹤0.01% 2672
2022
Q3 		$92K Buy
32,041
+7,106
+28% +$25.3K ﹤0.01% 2745
2022
Q2 		$87K Buy
24,935
+700
+3% +$2.74K ﹤0.01% 2782
2022
Q1 		$114K Buy
24,235
+2,482
+11% +$12.1K ﹤0.01% 2827
2021
Q4 		$131K Sell
21,753
-30,898
-59% -$215K ﹤0.01% 2832
2021
Q3 		$319K Sell
52,651
-2,600
-5% -$29.3K ﹤0.01% 2556
2021
Q2 		$691K Sell
55,251
-9,449
-15% -$102K ﹤0.01% 2225
2021
Q1 		$666K Buy
64,700
+31,600
+95% +$305K ﹤0.01% 2233
2020
Q4 		$301K Buy
+33,100
New +$238K ﹤0.01% 2420
2018
Q4 		– Sell
-22,759
Closed -$141K – 2583
2018
Q3 		$141K Buy
22,759
+719
+3% +$3.25K ﹤0.01% 2505
2018
Q2 		$141K Buy
22,040
+313
+1% +$2.23K ﹤0.01% 2500
2018
Q1 		$151K Buy
21,727
+11,202
+106% +$130K ﹤0.01% 2453
2017
Q4 		$133K Buy
+10,525
New +$128K ﹤0.01% 2481

Other funds holding MDXG

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

T. Rowe Price Associates's MDXG Position: Q2 2026 in Review

T. Rowe Price Associates reduced its MiMedx Group (MDXG) stake by 16% in Q2 2026, selling an estimated $67.6K and leaving 95,989 shares worth $370K. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

T. Rowe Price Associates first reported a position in MDXG in Q4 2017 and has held it in 27 quarters since. The position peaked at $691K in Q2 2021. 226 funds tracked by Wall St. Rank hold MDXG as of Q2 2026.

  • T. Rowe Price Associates held 95,989 shares of MiMedx Group worth $370K as of Q2 2026.
  • T. Rowe Price Associates sold 18,535 MiMedx Group shares in Q2 2026, an estimated $67.6K.
  • MiMedx Group made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2764 holding.
  • T. Rowe Price Associates first reported a position in MiMedx Group in Q4 2017 and has held it in 27 quarters since.
  • T. Rowe Price Associates's MiMedx Group position peaked at $691K in Q2 2021.
  • 226 funds tracked by Wall St. Rank held MiMedx Group as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.